MedPath

Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa

Phase 2
Completed
Conditions
Otitis Externa
Otorhinolaryngologic Diseases
Ear Diseases
Otitis
Interventions
Drug: Ciprodexa Otic Foam
Registration Number
NCT01359098
Lead Sponsor
Otic Pharma
Brief Summary

The purpose of this study is to assess the Safety and Efficacy of Ciprodexa Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam), used once-a-day for 7 days for the treatment of Acute Diffuse Otitis Externa, compared to Ciprodex otic suspension used twice daily for 7 days.

Detailed Description

Acute otitis externa (AOE) is defined as a diffuse inflammation of the external ear canal, which may also involve the pinna and/or the tympanic membrane. AOE is one of the most common infections encountered by otolaryngologists, pediatricians and family physicians. Diagnosis of AOE requires rapid onset (generally within 48 hours) of symptoms and signs of ear canal inflammation which includes: A) otalgia (often severe), itching or fullness, sometimes accompanied by reduced hearing or jaw pain; B) tenderness of the tragus and/or pinna; and C) diffuse ear canal edema with or without erythema, sometimes accompanied by ear discharge (otorrhea).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Aged 3 years to 80 years old.
  • Have a clinical diagnosis of Acute Otitis Externa based on clinical observation and of presumed bacterial origin.
  • Intact tympanic membrane
  • Unilateral disease
Exclusion Criteria
  • Known allergy or sensitivity to Ciprofloxacin or other quinolones.
  • Clinical Diagnosis of chronic suppurative otitis media (CSOM), acute otitis media (AOM), involvement of middle ear effusion (MEE).
  • Patient has the non intact tympanic membrane.
  • Patient has a serious underlying disease.
  • Patients with known history of immune dysfunction/deficiency and those receiving immunosuppressive therapy.
  • Patients with history of Diabetes mellitus.
  • Patients with more than 80% of the ear canal occluded.
  • Pregnant or lactating patients.
  • Overt fungal Acute Otitis Externa.
  • Local ear canal abnormalities such as abscess, granulation or polyps.
  • Congenital abnormalities of the external auditory canal or obstructive bony exostosis in the treated ear.
  • Mastoid or other suppurative non-infectious ear disorder (e.g. cholesteatoma) in the treated ear.
  • Seborrheic dermatitis or other dermatological conditions of the external auditory canal which would complicate evaluation.
  • Current Infection requiring systemic antimicrobial therapy.
  • Current or previous use of topical or oral antibiotics (within 3 days) or long-acting antibiotics (within 7 days).
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ciprodex Otic SuspensionCiprodex Otic SuspensionCiprodex Sterile Otic Solution (Alcon, Inc.)
Ciprodexa Otic FoamCiprodexa Otic FoamCiprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
Primary Outcome Measures
NameTimeMethod
Clinical cure [lack of need of additional therapy]Between Day 8 and Day 14 [e.g. 7 days after completion of treatment] that lasts 7 days

Clinical cure \[lack of need of additional therapy\] confirmed by significant reduction or absence of the disease symptoms a) Otalgia/ear pain, b) tenderness with movement of pinna, c) edema/ear canal occlusion and d) ear discharge/otorrhea

Secondary Outcome Measures
NameTimeMethod
Otalgia/ear painAt Visit 1, [Day 1 ,Baseline visit], at Visit 2 [Day 3 - Day 4, during treatment] and at Visit 3 Test-of-cure [Day 8 to Day 14]

Ear pain as reported by the patient

Inflammation/ear edemaAt the test-of-cure visit [Day 8 to Day 14]
Ear discharge/otorrheaAt the test-of-cure visit [Day 8 to Day 14]
tenderness with movement of pinnaAt the test-of-cure visit [Day 8 - Day 14]

Trial Locations

Locations (7)

HaEmek Medical Center

🇮🇱

Afula, Israel

Soroka Medical Center

🇮🇱

Beer Sheva, Israel

Wolfson Medical Center

🇮🇱

Holon, Israel

Meir Medical Center

🇮🇱

Kfar Saba, Israel

Clalit Health Services - Raziel Clinic

🇮🇱

Natania, Israel

Maccabi Healthcare Services (H.M.O.)

🇮🇱

Tel Aviv, Israel

Sourasky Medical Center (Ichilov)

🇮🇱

Tel Aviv, Israel

HaEmek Medical Center
🇮🇱Afula, Israel

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.